HIGHLIGHTS
- Who: Andrei Leitao et al. from the University of São Paulo, Brazil have published the Article: Therapeutic targeting of PARP with immunotherapy in acute myeloid leukemia, in the Journal: (JOURNAL)
- How: The results indicated that combined of decitabine with talazoparib is well-tolerated and that pharmacodynamic effects can be expected in responsive patients (Baer et_al 2022).
- Future: Frontiers in Pharmacology Conclusions and future directions Patients with AML often achieve tumor remission after standard therapy but invariably die of relapse via various mechanisms such frontiersin.org 10.3389/fphar.2024.1421816 Combination with . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.